Eagle Health Investments’s Adaptive Biotechnologies ADPT Stock Holding History

Eagle Health Investments’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,214,860	Closed	-$5.95M	–	28
2023 Q4	$5.95M	Hold	1,214,860	–	–	1.21%	18
2023 Q3	$6.62M	Hold	1,214,860	–	–	1.46%	18
2023 Q2	$8.15M	Hold	1,214,860	–	–	1.52%	19
2023 Q1	$10.7M	Buy	1,214,860 +607,000	+100%	+$5.35M	2.09%	17
2022 Q4	$4.64M	Sell	607,860 -607,000	-50%	-$4.72M	1.07%	17
2022 Q3	$8.65M	Hold	1,214,860	–	–	1.99%	18
2022 Q2	$9.83M	Buy	1,214,860 +200,000	+20%	+$1.76M	2.29%	19
2022 Q1	$14.1M	Buy	1,014,860 +264,100	+35%	+$4.15M	3.47%	16
2021 Q4	$21.1M	Buy	750,760 +309,294	+70%	+$9.48M	5.13%	6
2021 Q3	$15M	Buy	441,466 +183,639	+71%	+$6.64M	4.76%	12
2021 Q2	$10.5M	Buy	257,827 +55,607	+27%	+$2.16M	3.61%	14
2021 Q1	$8.14M	Buy	202,220 +118,685	+142%	+$6.42M	3.2%	14
2020 Q4	$4.94M	Buy	+83,535	New	+$4.31M	3.16%	15

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Eagle Health Investments's ADPT Position: Q1 2024 in Review

Eagle Health Investments sold out of Adaptive Biotechnologies (ADPT) in Q1 2024, closing a stake of 1,214,860 shares — an estimated $5.95M sold.

Eagle Health Investments first reported a position in ADPT in Q4 2020 and held it in 13 quarters. The position peaked at $21.1M in Q4 2021. 190 funds tracked by Wall St. Rank hold ADPT as of Q1 2024.

Eagle Health Investments reported no remaining Adaptive Biotechnologies position as of Q1 2024 after selling out during the quarter.
Eagle Health Investments sold 1,214,860 Adaptive Biotechnologies shares in Q1 2024, an estimated $5.95M.
Eagle Health Investments first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 13 quarters.
Eagle Health Investments's Adaptive Biotechnologies position peaked at $21.1M in Q4 2021.
190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2024.

Based on Eagle Health Investments's 13F filing for Q1 2024, filed 14 May 2024.